For more information about this medication, please contact the local representative of the marketing authorization holder:
Grifols Movaco, S.A.
Can Guasc, s/n – Parets del Vallès
08150 Barcelona
Spain
Date of the last review of this leaflet: 05/2020
This information is intended solely for healthcare professionals:
Special warnings and precautions for use
The colloid osmotic effect of human albumin at 200g/l is approximately four times that of blood plasma. Therefore, when administering concentrated albumin, ensure adequate hydration of the patient. Patients should be closely monitored to avoid circulatory overload and hyperhydration.
Albumin solutions should not be diluted with water for injection preparations, as this may cause hemolysis in recipients.
If large volumes need to be replenished, coagulation and hematocrit controls should be performed. Caution should be exercised to ensure adequate substitution of other blood constituents (coagulation factors, electrolytes, platelets, and red blood cells).
Hypervolemia may occur if the dose and infusion rate are not adjusted to the patient's circulatory status.
No confirmed cases of virus transmission have been reported with albumin manufactured according to the specifications and processes established inthe European Pharmacopoeia.
Interaction with other medications and other forms of interaction
No specific interactions of human albumin with other medications are known.
Dosage and administration
Dosage
The required dose will be based on the measurement of the circulating volume and not on the determination of albumin plasma levels.
When administering human albumin, the patient's hemodynamic situation should be regularly evaluated; this may include:
- arterial blood pressure and pulse
- central venous pressure
- pulmonary artery occlusion pressure
- diuresis
- electrolytes
- hematocrit/hemoglobin
Administration
Intravenous route.
The solution may be administered directly intravenously, or it may be diluted in an isotonic solution (e.g., sodium chloride 0.9%).
During plasmapheresis, the infusion rate should be adjusted to the exchange rate.
Notes for handling
Albumin solutions should not be diluted with water for injection preparations, as this may cause hemolysis in recipients.
If large volumes are administered, the product should be brought to room temperature or body temperature before use.
The solution should be transparent or slightly opalescent. Do not use solutions that are turbid or have deposits, which may indicate that the protein is unstable or that the solution has become contaminated.
Once the vial has been opened, the contents should be used immediately.
The disposal of unused medication and all materials that have come into contact with it will be carried out in accordance with local regulations.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.